Auna Announces 2Q25 Financial Results Adjusted EBITDA increases 5% FXN YoY with all segments contributing positively to quarterly results in their local currency Luxembourg

Announces 2Q25 Financial Results

EBITDA increases 5% FXN YoY with all segments contributing

positively to quarterly results in their local currency

Luxembourg, Aug 19, 2025 - Auna (NYSE:

AUNA) ("Auna" or the "Company"), a leading healthcare platform in Latin America with operations in Mexico,

Peru, and Colombia, today announced financial results for the second quarter ended June 30, 2025 ("second quarter 2025" or

"2Q25"). Financial results are expressed in Peruvian Soles ("S/" or PEN") and are presented in accordance

with International Financial Reporting Standards ("IFRS"), unless otherwise noted.

2Q25 Consolidated Highlights

from Auna's Executive Chairman and President

Auna grew its year-over-year ("YoY")

FX-neutral Adjusted EBITDA by 5%, with all three country segments contributing positively to our performance recovery in local currency

terms. Despite significant foreign exchange headwinds-particularly the depreciation of the Mexican and Colombian currencies versus

the Peruvian Sol- each operation demonstrated resilience to execute its strategy with utmost discipline with the goal of delivering

clinical and operational excellence, showcasing the power of our diversified geographic footprint.

We continue to build a stronger, more efficient

organization, while positioning Auna to effectively seize the near to long-term growth opportunities in Mexico's massive private

healthcare market. In Mexico, we have contained and stabilized the adverse effects related to physician/supplier relationships that temper

the implementation of the AunaWay, in particular with respect to patient/physician alignment and cost containment for payors. Improvements

in pricing and service mix, coupled with continued cost discipline, enabled us to grow EBITDA despite lower surgical volumes. This quarter

also marked significant progress on key strategic initiatives in Mexico, including

recruitment and integration of lead medical directors

and physicians, productivity programs, expansion of the Oncosalud network outside of Monterrey, and selective capital deployment. In Peru,

revenue growth across both Oncosalud and our healthcare network was supported by plan membership expansion, further price adjustments,

and service volume increases, even as we expanded healthcare capacity. In Colombia, the risk-sharing models we have been implementing

since last year are gaining additional traction, while collections commitments from intervened payors have been received on time as of

the end of the quarter, reducing the need for impairment provisions as well as improvement in margins and cash flow.

Looking ahead, we continue to work on the optimization

of our capital structure. We improved our maturity profile and maintained our Leverage Ratio at 3.6x, while continuing to target a medium-term

We are confident that the regional healthcare platform

we are building-focused on high-complexity care, integrated care delivery, and disciplined capital allocation-positions Auna

for further growth and long-term value for all stakeholders.

Overview of 2Q25 Consolidated Results

Revenues decreased 2% YoY to S/1,094

million, increasing 4% FXN, with revenues in local currency ("L.C.") increasing 5% in Mexico and 8% in Peru while remaining

flat versus 2Q24 in Colombia. In Mexico, healthcare network revenue increased, supported by higher tickets associated with high complexity

services and an improved pricing mix in other non-core services. The Peruvian healthcare network benefited from higher demand for surgeries,

membership growth, as well as price adjustments. In Colombia, the YoY growth in risk-sharing models supported the top line amidst a reduced

service offering for intervened EPSs, the local insurance companies.

Adjusted EBITDA decreased 3% YoY,

increasing 5% FXN, to S/241 million, with the margin flat at 22.1%. In L.C. terms, Adjusted EBITDA increased 2% in Mexico, 8% in Peru

and 9% in Colombia. The increase in FXN Adjusted EBITDA reflects revenue growth in Mexico and Peru, as well as expenses that support growth,

including investments in medical talent in Mexico and Peru, and sales commissions at Oncosalud. In Colombia, Adjusted EBITDA, included

lower impairment provisions. Additionally, the results in Auna's reporting currency were impacted by a 16% depreciation of MXN versus

PEN and 9% depreciation of COP versus PEN.

Net finance costs were S/46 million

in 2Q25 versus S/182 million in 2Q24. Net finance costs, excluding FX effects, would have been S/115 million in 2Q25 and S/133 million

in 2Q24, a decrease of S/18 million or 13%. The FX impact in 2Q25 includes a positive non-cash amount of S/68 million versus

a negative S/49 million non-cash FX impact from 2Q24, mainly due to the effect of the appreciation of the Peruvian Sol against the US

Dollar outside the range of Auna's call-spread hedge.

Net Income was S/84 million in

2Q25 compared to S/8 million in 2Q24. On a per-share basis, Auna reported Net Income of S/1.10, based on a weighted average number of

basic and diluted shares of 74,217,754.

Adjusted Net Income was S/89 million

in 2Q25, versus S/13 million in 2Q24. On a per-share basis, Auna reported Adjusted Net Income of S/1.17, based on a weighted average number

of basic and diluted shares of 74,217,754.

Business performance

(Explanations of variances are

in local currency unless expressed otherwise)

Auna s Healthcare Services and Oncosalud's

operations in Mexico accounted for 25% of consolidated revenues and 36% of consolidated Adjusted EBITDA.

(Figures in millions of Soles

and millions of US Dollars, unless expressed otherwise)

Segment revenue from Mexico increased 5%

YoY in 2Q25. Despite a YoY decline in demand for surgeries and emergency treatments in a soft market, revenues were supported

by higher average tickets for these services. Additionally, growth was fueled by the rebalancing of the pricing mix in other service lines,

including hemodynamics, radiotherapy, hemodialysis, and chemotherapy. However, the reduction in surgical procedures and emergency visits,

which serve as key entry points for patient intake, had a downstream impact, leading to fewer hospitalizations and ICU admissions.

Segment Adjusted EBITDA increased 2% YoY

in 2Q25, mainly due to revenue growth and cost efficiency measures implemented in 4Q24, particularly in pharmaceutical procurement and

surgical equipment rentals. Resulting cost savings were partially offset by higher expenses associated with initiatives to enhance physician

productivity, including incentive programs linked to the integration of Opcion Oncologia's medical staff. Mexico's Adjusted

EBITDA Margin remained healthy at 32.0%, despite a 1.1 p.p. decline from 2Q24.

PERU OPERATIONS: HEALTHCARE

SERVICES PERU AND ONCOSALUD PERU

Auna s Healthcare Services and Oncosalud

Peru accounted for 43% of consolidated revenues and 42% of consolidated Adjusted EBITDA.

(Figures in millions of Soles

and millions of US Dollars, unless expressed otherwise)

Total revenue from Peru increased 8% YoY

to S/474 million in 2Q25. The 7% YoY increase in revenues at the Oncosalud Peru segment reflects an increase of 10% in total plan memberships,

as well as the effect of annual price adjustments to support medical inflation in the Oncology and Healthcare plans. The MLR decreased

3.7 p.p. to 54.9%, led by an increase of General Healthcare plans in the product mix, while the Oncology MLR decreased for a fourth consecutive

quarter to 49.8%, a 4.9 p.p. decrease, due to efficiencies in pharmaceutical costs.

The Healthcare Services segment increased revenues

by 5% YoY, reflecting higher surgery volumes as well as improved pricing and service mix in Lima. Outside of Lima, Clinica Vallesur and

Clinica Chiclayo also contributed to revenue growth in the same way, in addition to increased volumes in emergency visits and outpatient

treatments at these care facilities.

Additionally, we added 47 operating beds across

the network, mostly at Clinica Delgado and Clinica Miraflores in Piura, where we also added 10 beds to its total capacity. As a result,

operating capacity utilization was 75.6%, and the total capacity utilization was 73.6%.

Consolidated Adjusted EBITDA in Peru increased

8% YoY to S/101 million in 2Q25, maintaining the margin flat at 21.3% versus 2Q24. The growth in Consolidated Adjusted EBITDA in Peru

was primarily driven by higher revenues, while COGS and SG&A increased to support the growth of Peruvian operations, including sales

commissions, expenses related to medical and administrative staff retention, and third-party medical services. On an individual segment

basis, the Adjusted EBITDA from Healthcare Services Peru decreases 15% mostly due to expense allocations from the Oncosalud Peru segment,